T cell receptor peptide therapy for autoimmune disease

Arthur A. Vandenbark, Yuan K. Chou, Dennis N. Bourdette, Ruth Whitham, George A. Hashim, Halina Offner

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


Synthetic peptides corresponding to germline T cell receptor (TCR) Vβ sequences shared by encephalitogenic T cells can prevent and treat experimental autoimmune encephalomyelitis in rats. The operative mechanism apparently involves boosting of anti-TCR immunity that develops during the course of experimental autoimmune encephalomyelitis (EAE), leading to the induction of autoregulatory T cells and antibodies. Striking parallels are present between patients with multiple sclerosis and animals with EAE in the T cell frequency and TCR V gene bias of BP reactive T cells, suggesting the involvement of an encephalitogenic process in multiple sclerosis. Preliminary trials with the appropriate human TCR peptides indicate that anti-TCR immunity can be boosted efficiently and safely, with concomitant loss of BP response, thus providing an effective strategy for selective regulation of autoimmunity in man.

Original languageEnglish (US)
Pages (from-to)83-92
Number of pages10
JournalJournal of Autoimmunity
Issue numberSUPPL. A
StatePublished - Apr 1992

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'T cell receptor peptide therapy for autoimmune disease'. Together they form a unique fingerprint.

Cite this